Clinical Trials
Our physicians at Retina Specialists are nationally recognized and actively involved in multi-centered clinical trials on novel therapeutic approaches to vitreoretinal diseases. Our research team is committed to carefully selecting well-designed, safe clinical studies that offer promising and exciting new treatments for our patients. Our clinical trials are a valuable opportunity for patients to access novel treatments for Vitreoretinal diseases.
For more information or to refer a patient for evaluation, please contact our Clinical Trials Coordinator: Debbie Bolling at 972-599-9098 or dbolling@retinaspecialists.net
We participate in numerous active national eye research studies, including:
Diabetic Retinopathy:
- KESTREL (Protocol CRTH258B2301): Study of Efficacy and Safety of Brolucizumab v Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema
- Clinical Trials.Gov Identifier: NCT03481634
- Principal Investigator: Santosh Patel, MD
- Sponsor: Novartis Pharmaceuticals
- Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
- Status: Not Yet Recruiting or Enrolling
Retinal Vein Occlusion:
TOPAZ (CLS1003-302): Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects with Macular Edema Following RVO
- Clinical Trials.Gov Identifier: NCT03203447
o Principal Investigator: Henry Choi, MD
- Sponsor: Clearside Biomedical
- Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
- Status: Active and Recruiting
Age-Related Macular Degeneration:
- HAWK STUDY EXTENSION (CRTH258A2301-E1): Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
- Clinical Trials.Gov Identifier: NCT03386474
o Principal Investigator: Santosh C. Patel, MD
- Sponsor: Novartis Pharmaceuticals
- Study Coordinator: Debbie Bolling (dbolling@retinaspecialists.com)
- Status: Enrollment closed